BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience Research

Executive Summary: BIIE 0246 is a highly selective Y2 receptor antagonist that binds with nanomolar affinity (IC₅₀ 3.3 nM) and blocks neuropeptide Y (NPY)-mediated presynaptic inhibition in neural tissues (ApexBio). It fully inhibits PYY3-36-induced contractions in rat colon and attenuates PYY(3-36)-mediated feeding suppression, demonstrating utility in satiety and behavioral research (Fan et al., 2024). BIIE 0246's anxiolytic-like effects in validated behavioral assays offer translational insights into NPY-Y2R signaling. The compound is soluble at 67.2 mg/ml in DMSO, stable at 4°C, and recommended for research use only. It serves as a key tool for dissecting the adipose-neural axis and translational applications in neurobehavioral and metabolic disease models.

Biological Rationale

Neuropeptide Y (NPY) is a conserved 36-amino acid peptide neurotransmitter involved in appetite regulation, energy balance, and stress responses. NPY exerts its functions via a family of G-protein-coupled receptors: Y1, Y2, Y4, and Y5. The Y2 receptor (Y2R) is predominantly presynaptic and acts as an autoreceptor to inhibit further NPY release, thereby modulating synaptic transmission and plasticity (Fan et al., 2024). Dysregulation of NPY-Y2R signaling is implicated in disorders such as obesity, anxiety, and cardiac arrhythmias. Recent studies highlight the adipose-neural axis—where adipocyte-derived factors like leptin and NPY interact with neural circuits—as a pivotal mediator of cardiometabolic disease states (Fan et al., 2024). The ability to selectively antagonize Y2R is essential for elucidating its role in these complex biological processes.

Mechanism of Action of BIIE 0246

BIIE 0246 (C₄₉H₅₇N₁₁O₆, MW 896.06) is a non-peptidic, highly selective antagonist of the NPY Y2 receptor. It binds to Y2R with an IC₅₀ of 3.3 nM and Ki values between 8–15 nM for PYY3-36 binding sites, as measured via competitive radioligand assays (ApexBio). By occupying the orthosteric site, BIIE 0246 prevents endogenous NPY or PYY3-36 from activating Y2R. This antagonism blocks presynaptic inhibition of neurotransmitter release, resulting in enhanced synaptic activity. In rat hippocampal slices, BIIE 0246 abolishes NPY-induced inhibition of primary afterdischarge and population excitatory postsynaptic potentials (EPSPs). In peripheral tissues, it suppresses Y2R-mediated contractions in the colon and attenuates satiety signaling. These effects are dose-dependent and specific to Y2R, with negligible off-target activity at Y1 or Y5 receptors under tested conditions (Fan et al., 2024).

Evidence & Benchmarks

• BIIE 0246 binds to the rat neuropeptide Y Y2 receptor with an IC₅₀ of 3.3 nM and Ki values of 8–15 nM for PYY3-36 binding sites (ApexBio).
• BIIE 0246 completely blocks PYY3-36-induced contraction in isolated rat colon tissue (10^-7 M, ex vivo) (ApexBio).
• In rat hippocampal slices, BIIE 0246 reverses NPY-induced inhibition of primary afterdischarge activity and population EPSPs (1 μM, in vitro) (ApexBio).
• Systemic administration of BIIE 0246 attenuates PYY(3-36)-induced reduction in food intake in rodents, supporting a role in post-prandial satiety modulation (Fan et al., 2024).
• BIIE 0246 produces anxiolytic-like effects in elevated plus-maze behavioral assays at doses of 0.5–2 mg/kg (i.p., mouse model) (ApexBio).
• Recent in vitro coculture models show that the leptin-NPY axis is a key mediator in arrhythmogenesis and that NPY receptor antagonism is a promising intervention target (Fan et al., 2024).

For in-depth mechanistic and translational analysis, see "BIIE 0246: Unlocking Y2R Antagonism for Precision Neurosc...", which provides foundational context. This article extends those insights with new evidence from arrhythmia models and updated benchmarks.

Applications, Limits & Misconceptions

BIIE 0246 is widely used to interrogate the function of Y2R in neural, peripheral, and behavioral models.

• Neuroscience: Dissects presynaptic NPY-Y2R signaling in hippocampal and hypothalamic circuits.
• Behavioral pharmacology: Evaluates anxiolytic and satiety responses in rodent models.
• Metabolic research: Probes adipose-neural crosstalk and feeding behavior via selective Y2R blockade.
• Cardiometabolic disease: Investigates the role of NPY in arrhythmogenesis and sympathetic activation in models of epicardial adipose tissue expansion (Fan et al., 2024).

For strategic translational perspectives, see "Dissecting the Adipose-Neural Axis: Strategic Insights fo...", which this article updates by providing more recent evidence from cell-based arrhythmia models.

Common Pitfalls or Misconceptions

• BIIE 0246 is selective for Y2R but does not antagonize Y1, Y4, or Y5 receptors at standard concentrations; using it to study these subtypes is inappropriate.
• It is not suitable for clinical or diagnostic use, as it is for research purposes only (ApexBio).
• BIIE 0246's effects are dose-dependent and may not translate linearly across species or tissue types; direct extrapolation to human models is not validated.
• Long-term stability of reconstituted solutions is not guaranteed; fresh aliquots are recommended for each experiment.
• Interpretation of behavioral effects must control for off-target or systemic effects at high concentrations.

Workflow Integration & Parameters

BIIE 0246 is supplied as a white solid (SKU: B6836). It is soluble at up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol. Store the lyophilized powder at 4°C in a sealed container. For experimental use, dissolve immediately before application; do not store solutions long-term. Standard in vitro concentrations range from 100 nM to 1 μM, while in vivo rodent studies use 0.5–2 mg/kg (intraperitoneal injection). Verify batch purity and confirm receptor selectivity with appropriate controls. For detailed workflows, see "Rewiring Translational Research: Strategic Dissection of ...", which is complemented here with updated storage and handling guidance.

Conclusion & Outlook

BIIE 0246 remains a gold-standard tool for selective Y2R antagonism in neuroscience, metabolic, and cardiovascular research. Its high potency and specificity enable robust dissection of NPY-mediated presynaptic inhibition, feeding behavior, and adipose-neural crosstalk. Ongoing studies using stem cell-based models and in vivo systems continue to expand its translational relevance, especially in the context of arrhythmia and post-prandial satiety (Fan et al., 2024). For next-generation applications and emerging mechanistic insights, see the comparative discussion in "BIIE 0246 and the Adipose-Neural Axis: Redefining Transla...", which this article extends with new benchmarks and workflow parameters.